Original Article

Cnidium lactone stimulates osteogenic differentiation of bone marrow mesenchymal stem cells via BMP-2/smado-signaling cascades mediated by estrogen receptor

Zhao Wang, Hong-Wei Bao

Department of Orthopaedics, Jingjiang People’s Hospital, No. 28, Zhongzhou Road, Jingjiang, Taizhou 214500, Jiangsu Province, China

Received June 26, 2019; Accepted July 18, 2019; Epub August 15, 2019; Published August 30, 2019

Abstract: Our aim was to study the osteogenic effect of cnidium lactone for bone marrow mesenchymal stem cells (BMSCs) and its potential mechanism. BMSCs were isolated and identified by flow cytometry and multidirectional differentiation capacity. Cell Counting Kit-8 (CCK-8) was used to identify the optimal concentration of cnidium lactone. Alkaline Phosphatase (ALP) and Alizarin Red S (ARS) was performed to identify whether cnidium lactone has effect on osteogenesis at early and late phase respectively. Moreover, we used estrogen receptor antagonist, ICI182780, to identify the receptor of cnidium lactone. The expression of Runt-related transcription factor 2 (RUNX2), Osterix (OSX), osteopontin (OPN), estrogen receptor (ER), Smad4, p-Smad1, Smad1 and bone morphogenetic protein 2 (BMP-2) protein were measured by PCR and western blot. Cnidium lactone (2 μM) demonstrated increased osteogenesis after osteogenic inducible medium (OIM) induction, as evidenced by more ALP activity and mineralization. When blocked with ICI182780, osteogenesis capacity was decreased. Moreover, the polymerase chain reaction (PCR) and western blotting results indicated that cnidium lactone enhanced ER, BMP2, Smad1, Smad4, RUNX2, OSX, and OPN expression and Smad1 phosphorylation. Cnidium lactone can effectively stimulates osteogenic differentiation of BMSCs via BMP-2/Smado-Signaling cascades mediated by ER.

Keywords: Cnidium lactone, bone marrow mesenchymal stem cells, smado signaling, estrogen receptor

Introduction

Osteoporosis (OP) is a harmful disease with the high incidence that resulting in elevated fracture risk [1, 2]. OP is mainly due to excessive bone resorption and decreased bone formation. Bone mesenchymal stem cells (BMSCs) are a class of cells with multipotency and can fully differentiate towards various cell types such as osteoblasts, chondrocytes and adipocytes [3, 4]. Due to multi-directional differentiation properties, BMSCs are a potential cell source for bone regeneration. Recent studies shown that transplant with BMSCs and promotion of osteogenic differentiation is a hot topic.

Cnidium lactone is a fundamental component with pharmacological activity extracted from Chinese Medicine cnidium monnieri [5]. Cnidium lactone has been reported to inhibit osteoclastogenesis to prevent ovariectomy-induced bone loss in mice [6]. In vitro experiment found that cnidium lactone inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by receptor activator of nuclear factor-κB ligand (RANKL) [7]. Estrogen combined with estrogen receptor (ER) and promote bone formation. BMP-2, a member of the transforming growth factor-beta (TGF-β) superfamily, plays a vital role in inducing osteogenic differentiation of BMSCs [8]. The mature BMP-2 protein is secreted from cells, and can then act in a paracrine and/or autocrine manner. When BMP-2 binds to corresponding receptors, then downstream genes were up-regulated and finally stimulate bone formation [9, 10]. Hsieh et al. [11] transfection of BMP-2 to BMSCs could induce osteo-
blast differentiation in a rat calvarial defect model. BMP-2/Smad signaling pathway is crucial for bone remodeling. Li et al. [12] found that Macrolactin F promotes osteoblastogenesis through a BMP-2/Smad/Akt/Runx2 signaling pathway. Dong et al. [13] revealed that silicon stimulates collagen type 1 and osteocalcin synthesis in Human Osteoblast-Like Cells through the BMP-2/Smad/RUNX2 signaling pathway.

All in all, these studies revealed that cnidium lactone is a potential new drug for treating osteoporosis. However, whether cnidium lactone could stimulate osteogenic differentiation of BMSCs through ER/BMP-2/Smad signaling cascades was unknown.

**Materials and methods**

**BMSC and cnidium lactone preparation**

Rat BMSCs was isolated from Sprague Dawley (SD) rats according to previously reports [14]. Rats femurs and tibias were harvested from 21-days-old rats, and then the bone marrow stromal cells were flushed out from the bone marrow cavity with a syringe and culture in complete medium with 20% fetal bovine serum (FBS) at 37°C and 5% CO₂. After 24 h period culture, unattached cells were discarded. Medium was replaced every 3 days. Passages 3 BMSCs were used for experiment. We used flow-cytometric analysis to characterize their immunophenotype, and mesenchymal and non-mesenchymal stem cell-associated surface markers were measured.

Antibodies combined with phycoerythrin (PE), fluorescein isothiocyanate (FITC) or APC against CD44, CD90, CD29, CD11b/c and CD 45 (TBD Science, Tianjin, China) were added into each tube loaded with nearly 5×10⁵ BMSCs/200 μl of PBS, and then the BMSCs were incubated for 1 hour at 4°C for further analyses. Flow cytometry was conducted by a FACSCanto™ II Flow Cytometer (BD Biosciences, San Jose, CA, USA).

To investigate the osteogenic differentiation potential, BMSCs were exposed to the osteogenic induced medium (OIM), which is complete medium supplemented with 10 nM dexamethasone, 10 ng/ml insulin, and 0.5 μM isobutyl-methylxanthine (IBMX) (Solarbio, Beijing, China). To investigate chondrogenic differentiation, We used DMEM supplemented with 10% FBS, penicillin (100 U/mL)/streptomycin (100 μg/mL), 10 μg/mL sodium pyruvate, 300 μg/mL L-glutamine, 40 μg/mL L-proline, 50 μg/mL L-ascorbic acid-2-phosphate, 1.5 mg/mL bovine serum albumin (BSA; Roche, San Francisco, CA, USA), 1× insulin-transferrin-selenium, 100 nM dexamethasone (all from Sigma, St Louis, MO, USA) and 10 ng/mL TGF-β3 to induce chondrogenic differentiation for 28 days.

Cnidium lactone was purchased from Aladdin Company (Shanghai, China) and was dissolved in DMSO. We used medium to diluent experiment concentration. And final concentration in each experiment group was less than 0.1%.

**Cell proliferation assay**

Cell Counting Kit-8 (CCK-8) (Solarbio, Beijing, China) was used to determine the cnidium lactone on cell viability and proliferation assays of BMSCs. BMSCs were seeded at 10000 cells in 96 well plates in triplicate and cultured in DMEM. BMSCs were cultured for 24 hours, then each well plates were treated with cnidium lactone at the different concentrations (0, 0.1, 1, 2, 4 and 8-μM) at 1, 3, 5 and 7 days. Each time point ends, 10 μL CCK-8 was added to every well, and plates were incubated at 37°C for 3 h. The absorbance was detected at 450 nm in a Spectra Max 190 Enzyme standard instrument (Molecular Devices).

**Alkaline phosphatase (ALP) activity assay**

After gelatine wrap the 6-well plates, BMSCs were seeded in 6-well plates and waited BMSCs reached 70% confluence. BMSCs were then divided into the following four groups: control group, OIM group, OIM+ cnidium lactone group (2 μM), E2 group. We further used estrogen receptor inhibitor ICI182780 to explore whether cnidium lactone could bind to the estrogen receptor to stimulate osteogenic differentiation. The concentration of ICI182780 was de-
Identification of BMSCs

Flow cytometry analysis results shown that BMSCs were positive for CD44, CD90, CD29 but negative for CD11b/c and CD45. BMSCs were capable of differentiation into adipocytes and chondrocytes, and were calcified under the proper conditions (Figure 1). In adipogenic medium, colonies stained well with oil red O. In calcification medium, colonies produced abundant calcium. In chondrogenic medium, much glycosaminoglycan was stained diffusely with toluidine blue (Figure 1).

Cnidium lactone enhanced cell proliferation

The effect of cnidium lactone on BMSCs viability was performed by CCK-8 assay. The results revealed that, as time extended, the number of
Cnidium lactone for osteogenesis

BMSCs in all different treating-groups increased gradually. However, following 1, 3 and 5 days treatment, the average number of viable cells in cnidium lactone group showed increase than control group (Figure 2). Among the five doses of cnidium lactone, 2 μM cnidium lactone possess the most obvious viable cells than other doses. At 5 days, only cnidium lactone with 2 μM has statistically significant than control group (P<0.05). There were no statistically significant different between the number of BMSCs in cnidium lactone and control group following 7 days treatment.

Cnidium lactone enhanced osteoblastic differentiation and extracellular matrix production and mineralization

Compared with the control group, BMSCs treatment with cnidium lactone (2 μM) demonstrated increased osteogenesis after OIM induction, as evidenced by more ALP activity and mineralization. E2 group has associated with no superior than cnidium lactone in terms of the ALP activity and mineralization (Figure 3).

Cnidium lactone upregulates osteoblast-specific marker gene expression

As shown in Figure 4, compared with control group, administration with cnidium lactone was associated with an increase of the expression of RUNX2, OSX, and OPN with statistically significant (P<0.05).

Treatment with cnidium lactone combined with OIM upregulated RUNX2, OSX, and OPN expres-
Cnidium lactone for osteogenesis

Figure 3. Effects of cnidium lactone on ALP staining and matrix mineralization. (A) General observation of ALP staining and ARS. Quantitative analysis of ALP activity (B) and calcium content (C) in each group. *P<0.05, vs control group.

Cnidium lactone for osteogenesis

Cnidium lactone regulates osteoblast-specific gene expression via the ER

The addition of 1 μM ICI182780 in cnidium lactone (2 μM) inhibited ALP activity and mineralization than cnidium lactone (2 μM) group. Meanwhile, cnidium lactone can rescue the inhibition of osteogenesis effect caused by ICI182780 (Figure 5).

Cnidium lactone regulates osteoblast marker protein expression

As shown in Figure 6, ERα, OPN, OSX and RUNX2 expression levels were upregulated compared with control group. Compared with control group, cnidium lactone group was associated with a reduction of the ERα, OPN, OSX and RUNX2 protein expression. In ICI group, when added 2 μM cnidium lactone, the ERα, OPN, OSX and RUNX2 protein expression could recover in some extent.

Discussion

BMSCs own multipotential in differentiation, and BMSCs has a prospective alternative autologous cell-based therapy for bone defect. BMSCs could differentiated into three types of
Cnidium lactone for osteogenesis

Figure 5. ALP activity and matrix mineralization was decreased by ICI182780.

Figure 6. Western-blot analysis of RUNX2, OSX, OPN, ERα, Smad4, p-Smad1, Smad1 and BMP-2.

Results found that 2 μM cnidium lactone was the most obvious dose that could stimulate BMSCs proliferation. Increasing in ALP activity and calcium nodule formation in cnidium lactone-treated BMSCs suggested that it promoted osteogenic differentiation, which was consistent with previous findings. Zhang et al. [16] revealed that cnidium lactone enhances osteogenesis in osteoblasts by elevating transcription factor Osterix (OSX) via cAMP/CREB signaling. Jia et al. [17] concluded that cnidium lactone may represent new pharmacological tools for the treatment of osteoporosis. Ming et al. [18] revealed that cnidium lactone could stimulate the osteoblastic differentiation of rat calvarial osteoblast cultures by the BMP-2/p38MAPK/Runx-2/osterix pathway.

BMP-2 pathway has been well-defined as a vital positive modulator of bone homeostasis [19, 20]. Activated type I BMP receptors propagate BMP signals by phosphorylating Smad1/5/8 [21]. We found that cnidium lactone could stim-
Cnidium lactone for osteogenesis

ulate the BMP-2 expression and subsequent Smad signaling. When blocked the ER by ICI, the expression of BMP-2 and Smad proteins were down-regulated. ALP and ARS staining has similar results. When blocked with ICI, ALP activity and calcium nodule formation were down-regulated with statistically significant. When added ICI in cnidium lactone, the ALP activity and calcium nodule formation could rescue to some degree. This result indicated that cnidium lactone partially combined with ERα and activate BMP-2/sm ad signaling pathway to induce osteogenic differentiation of BMSCs.

OPN, OSX and RUNX2 protein expression level were used for assess the osteogenic capacity. Compared with control group, cnidium lactone could significantly enhance the relative expression of OPN, OSX and RUNX2. When added ICI, the relative expression of OPN, OSX and RUNX2 was decreased than control group and cnidium lactone group. Thus, we speculated that cnidium lactone could bind with ER and subsequent stimulate BMP-2/Smad signaling pathway.

Previous studies BMP have a close relationship between estrogen receptor [22, 23]. Lee et al. [24] reported that dehydrodiconiferyl alcohol promotes BMP-2-induced osteoblastogenesis through its agonistic effects on estrogen receptor. When estrogen receptor activated, BMP-2 and subsequent Smad signaling was upregulated. Finally, BMSCs were differentiated and mineralization. Thus, we concluded cnidium lactone combined with ERα and other receptors, then activated BMP-2/Smad signaling pathway.

In conclusion, this research revealed that cnidium lactone binds to the receptor of ER and stimulated BMP/Smad signaling, then osteogenic-related genes were up-regulated and ultimately stimulated BMSCs differentiation and mineralization.

Disclosure of conflict of interest

None.

Address correspondence to: Hong-Wei Bao, Department of Orthopaedics, Jingjiang People's Hospital, No. 28, Zhongzhou Road, Jingjiang, Taizhou 214500, Jiangsu Province, China. E-mail: lianyunbi199103-13@126.com

References

Cnidium lactone for osteogenesis


[23] Foroughinia G, Fazileh A and Eghbalsaied S. Expression of genes involved in BMP and estrogen signaling and AMPK production can be important factors affecting total number of antral follicles in ewes. Theriogenology 2017; 91: 36-43.